| Current role of ischemia-modified albumin in routine clinical practice. | |
| | |
MedLine Citation:
|
PMID: 20874662 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
BACKGROUND: Ischemia-modified albumin has been proposed as a useful rule-out marker for the diagnosis of acute coronary syndrome in the emergency department. OBJECTIVE: To perform a review of ischemia-modified albumin use in the clinical practice. METHODS: We performed a comprehensive literature search by using electronic bibliographic databases. CONCLUSION: Although the main limitation of ischemia-modified albumin at present is its low specificity, it may be a useful test to rule out acute coronary syndrome from low to moderate pre-test probability conditions with negative cardiac troponins and a negative ECG. |
| | |
Authors:
|
Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez |
Publication Detail:
|
Type: Journal Article Date: 2010-09-29 |
Journal Detail:
|
Title: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals Volume: 15 ISSN: 1366-5804 ISO Abbreviation: Biomarkers Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9606000 Medline TA: Biomarkers Country: England |
Other Details:
|
Languages: eng Pagination: 655-62 Citation Subset: IM |
Affiliation:
|
Hospital Universitario de Canarias, Department of Cardiology, Tenerife, Spain. adrvdg@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: MHADIE's matrix to analyse the functioning of education systems.
Next Document: Integrating research into policy planning: MHADIE policy recommendations.